^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PF-07257876
i
Other names: PF-07257876
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pfizer
Drug class:
PD-L1 inhibitor, CD47 inhibitor
Related drugs:
25d
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (clinicaltrials.gov)
P1, N=29, Completed, Pfizer | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
PF-07257876
7ms
Addressing Domain Specificity in the Development of a Cell-Based Binding Assay for the Detection of Neutralizing Antibodies Against a CD47xPD-L1 Bispecific Antibody. (PubMed, AAPS J)
PF-07257876 is a bispecific antibody being developed for the treatment of certain advanced or metastatic solid tumors...Specifically, mock samples containing a mixture of NAb positive controls against both binding domains of the bispecific antibody produced false-negative results in the cell-based binding assay. An adaptation made to the standard BEAD approach restored domain-specific NAb detection, while also contributing to an assay sensitivity of 1 µg/mL in the presence of a clinically relevant drug tolerance level of up to 400 µg/mL.
Journal
|
PF-07257876
9ms
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (clinicaltrials.gov)
P1, N=28, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=90 --> 28 | Trial completion date: Mar 2026 --> Oct 2023 | Trial primary completion date: Nov 2024 --> Oct 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PF-07257876
11ms
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (clinicaltrials.gov)
P1, N=90, Recruiting, Pfizer | Trial primary completion date: Dec 2025 --> Nov 2024
Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PF-07257876
over1year
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (clinicaltrials.gov)
P1, N=90, Recruiting, Pfizer | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PF-07257876
almost2years
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (clinicaltrials.gov)
P1, N=90, Recruiting, Pfizer | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
Trial completion date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PF-07257876
over2years
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (clinicaltrials.gov)
P1, N=90, Recruiting, Pfizer | Not yet recruiting --> Recruiting
Clinical • Enrollment open • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PF-07257876
almost3years
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (clinicaltrials.gov)
P1, N=90, Not yet recruiting, Pfizer
Clinical • New P1 trial • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PF-07257876
Share via
